A class action suit has been proposed against Highmark Inc. arguing the company conspired with the University of Pittsburgh Medical Center to fix insurance rates. Highmark Inc. has responded by arguing the suit cannot go forward, citing a U.S. Supreme Court ruling that says damages cannot be awarded over charges involving anti-competitive behavior in rate pricing if those rate have already been approved by a regulation authority. A strategic partnership between Highmark Inc. and St. Vincent Health System had been agreed upon earlier last month in an effort for Highmark to become a stronger competitor against University of Pittsburgh Medical Center.
Featured News
Tech Policy and Regulation Weekly Roundup
Jan 23, 2026 by
CPI
Perkins Coie Adds Former DOJ Antitrust Leader as Partner in Washington
Jan 22, 2026 by
CPI
Ryanair Boss Dismisses Musk’s Buyout as Starlink Feud Escalates
Jan 22, 2026 by
CPI
Paramount Extends Warner Bros Bid as Netflix Rivalry Heats Up
Jan 22, 2026 by
CPI
South Korea Breaks New Ground With Landmark AI Law
Jan 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark Rosman & KaDee L. Ru